FDA Approves Scary New Drug

Statins are an incredibly common drug in America today. In fact, one in three Americans over age 40 take a statin.  Almost half of people over age 75 take a statin drug to reduce high cholesterol.

What many people don’t realize is the the side effects from these statin drugs can be worse than what they are intended to treat. Dr. Mercola says

“Statins have a long list of side effects, and may even lead to the very problem you’re trying to avoid — heart disease — as the drug inhibits both Coenzyme Q10 and vitamin K2.

Statins also reduce squalene, which can raise your risk of immune system dysfunction.

(The depletion of CoQ10 caused by the drug is why statins can increase your risk of acute heart failure. So if you’re taking a statin drug, you simply MUST take Coenzyme Q10 or ubiquinol as a supplement. You cannot get enough of it through your diet.)”

This makes statins a scary, and potentially counteractive, drug, yet, on July 24, 2015, the Food and Drug Administration (FDA) approved another statin drug for use. This new drug is called alirocumab and will be sold under the brand name Praluent. This drug is part of new class of drugs called PCSK9 inhibitors which affect the liver’s filtering functionality to cause the liver to reduce the amount of LDL in the body.

Besides the slippery slope that tends to happen with marketing campaigns (offer the drug to a small group and then reclassify a large number of people as potentially being in that small group), alirocumab has potentially serious side effects. Again, Dr. Mercola writes:

“This despite the fact that results from a 78-week long study7,8 published in the New England Journal of Medicine in April this year, shows that alirocumab (Praluent) causes higher incidence of many of the same side effects as statins:

  • 1.2 percent of patients who received both a statin and bi-weekly injections of Praluent experienced neurocognitive problems, such as memory impairment or confusion, compared to 0.5 percent of those taking a statin only
  • 5.4 percent of those receiving statin plus Praluent suffered myalgia (muscle pain) compared to 2.9 percent of the statin only group
  • 2.9 percent of the statin/Praluent group experienced eye problems, compared to 1.9 percent of the statin only group”

Unfortunately, alirocumab appears to be yet another money grab by big pharma at the expense of the pocketbooks and health of people worldwide.

Leave a Reply